S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Sell every Stock except ONE (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Former Deutsche Bank Co-CEO Anshu Jain dies
Saudi Aramco's profits already $88B as oil prices stay high
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Sell every Stock except ONE (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Former Deutsche Bank Co-CEO Anshu Jain dies
Saudi Aramco's profits already $88B as oil prices stay high
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Sell every Stock except ONE (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Former Deutsche Bank Co-CEO Anshu Jain dies
Saudi Aramco's profits already $88B as oil prices stay high
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Sell every Stock except ONE (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Former Deutsche Bank Co-CEO Anshu Jain dies
Saudi Aramco's profits already $88B as oil prices stay high
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:GLMD

Galmed Pharmaceuticals - GLMD Stock Forecast, Price & News

$0.41
-0.03 (-6.82%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.39
$0.44
50-Day Range
$0.41
$0.65
52-Week Range
$0.38
$3.39
Volume
215,780 shs
Average Volume
112,427 shs
Market Capitalization
$10.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Galmed Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,119.1% Upside
$5.00 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.05mentions of Galmed Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.69) to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

763rd out of 1,135 stocks

Pharmaceutical Preparations Industry

390th out of 557 stocks

GLMD stock logo

About Galmed Pharmaceuticals (NASDAQ:GLMD) Stock

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Trading Down 6.7 %

Shares of NASDAQ:GLMD traded down $0.03 during trading on Friday, hitting $0.41. The company's stock had a trading volume of 215,780 shares, compared to its average volume of 112,427. The business has a 50 day moving average price of $0.53 and a two-hundred day moving average price of $1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.48. Galmed Pharmaceuticals has a fifty-two week low of $0.38 and a fifty-two week high of $3.39.

Galmed Pharmaceuticals (NASDAQ:GLMD - Get Rating) last posted its quarterly earnings results on Tuesday, May 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.09. On average, sell-side analysts forecast that Galmed Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Analyst Ratings Changes

GLMD has been the topic of several analyst reports. Canaccord Genuity Group lowered shares of Galmed Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, August 8th. Maxim Group lowered shares of Galmed Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, August 8th. Raymond James downgraded shares of Galmed Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 18th. Cantor Fitzgerald downgraded shares of Galmed Pharmaceuticals from an "overweight" rating to a "neutral" rating in a report on Thursday, August 4th. Finally, HC Wainwright downgraded shares of Galmed Pharmaceuticals from a "buy" rating to a "neutral" rating in a report on Tuesday, May 3rd. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $5.00.

Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Stock News Headlines

Galmed Pharmaceuticals Shares Down 16%
Galmed Pharmaceuticals's Earnings Outlook
See More Headlines
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Company Calendar

Last Earnings
5/17/2022
Today
8/14/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLMD
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,119.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-32,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.83 per share

Miscellaneous

Free Float
N/A
Market Cap
$10.29 million
Optionable
Optionable
Beta
1.34

Key Executives

  • Mr. Allen Baharaff (Age 57)
    Co-Founder, Pres, CEO & Chairman
    Comp: $1.71M
  • Mr. Guy Nehemya (Age 37)
    COO & Data Protection Officer
    Comp: $168.93k
  • Mr. Yohai Stenzler CPA (Age 39)
    Chief Accounting Officer
    Comp: $173.11k
  • Dr. Liat Hayardeny (Age 55)
    Chief Scientific Officer
    Comp: $263.01k
  • Mr. Doron Cohen (Age 55)
    Chief Financial Officer
  • Ms. Yael Hollander (Age 39)
    VP of Legal Affairs & Strategy
  • Ms. Shani Ganon
    HR Mang.
  • Dr. Tali Gorfine (Age 52)
    Medical Consultant
  • Mr. Niv Alon
    Head of PMO
  • Ms. Topaz Falkoviz Arbel
    Corp. Sec.













GLMD Stock - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View GLMD analyst ratings
or view top-rated stocks.

What is Galmed Pharmaceuticals' stock price forecast for 2022?

5 brokers have issued 12 month price targets for Galmed Pharmaceuticals' shares. Their GLMD share price forecasts range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 1,119.1% from the stock's current price.
View analysts price targets for GLMD
or view top-rated stocks among Wall Street analysts.

How have GLMD shares performed in 2022?

Galmed Pharmaceuticals' stock was trading at $1.82 on January 1st, 2022. Since then, GLMD stock has decreased by 77.5% and is now trading at $0.4101.
View the best growth stocks for 2022 here
.

When is Galmed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our GLMD earnings forecast
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.09.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Western Wealth Management LLC (0.24%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $0.41.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $10.29 million. The biopharmaceutical company earns $-32,470,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for the company is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447.

This page (NASDAQ:GLMD) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.